https://pharminent.com/in-alzheimers-bristol-myers-sees-big-promise-beyond-amyloid/ 2026-05-21T15:49:10Z Pharminent en In Alzheimer's, Bristol Myers sees big promise beyond amyloid 2026-05-21T13:00:00Z Blog https://pharminent.com/lillys-triple-agonist-shows-bariatric-surgery-like-weight-loss-results/ 2026-05-21T15:49:43Z Pharminent en Lilly's triple agonist shows bariatric surgery-like weight loss results 2026-05-21T12:55:42Z Blog https://pharminent.com/lilly-bms-incyte-strike-deals-to-keep-biopharmas-ai-integration-rolling/ 2026-05-21T15:49:54Z Pharminent en Lilly, BMS, Incyte strike deals to keep biopharma's AI integration rolling 2026-05-21T11:29:44Z Blog https://pharminent.com/eli-lilly-maintains-ma-streak-with-202m-engage-bio-buyout/ 2026-05-21T15:50:05Z Pharminent en Eli Lilly maintains M&A streak with $202m Engage Bio buyout 2026-05-21T10:22:38Z Blog https://pharminent.com/bayer-gets-swift-review-for-kerendia-in-type-1-diabetes/ 2026-05-21T15:50:14Z Pharminent en Bayer gets swift review for Kerendia in type 1 diabetes 2026-05-21T09:41:08Z Blog https://pharminent.com/ats-2026-long-term-data-show-durable-benefit-of-trikafta-for-cystic-fibrosis/ 2026-05-21T15:50:35Z Pharminent en ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis 2026-05-21T09:30:18Z Blog https://pharminent.com/80900-2/ 2026-05-20T23:55:49Z Pharminent en 2026-05-20T23:55:43Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-may-20-2026/ 2026-05-20T23:41:55Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • May 20, 2026 2026-05-20T23:41:40Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-may-20-2026/ 2026-05-20T19:13:55Z Pharminent en Manufacturing Intelligence • Weekly Digest • May 20, 2026 2026-05-20T19:13:48Z Blog https://pharminent.com/remepys-hybrid-parkinsons-therapy-poised-for-phase-3/ 2026-05-21T15:51:00Z Pharminent en Remepy's hybrid Parkinson's therapy poised for phase 3 2026-05-20T19:11:27Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-20-2026/ 2026-05-20T17:23:37Z Pharminent en Strategic News Watch • May 20, 2026 2026-05-20T17:23:17Z Blog https://pharminent.com/immunovants-potential-autoimmune-blockbuster-waves-rna-editing-update/ 2026-05-20T15:55:07Z Pharminent en Immunovant's potential autoimmune 'blockbuster'; Wave's RNA editing update 2026-05-20T14:43:50Z Blog https://pharminent.com/pazdur-declines-to-announce-candidacy-for-vacated-fda-commissioner-role/ 2026-05-20T15:55:27Z Pharminent en Pazdur declines to announce candidacy for vacated FDA commissioner role 2026-05-20T14:32:30Z Blog https://pharminent.com/80847-2/ 2026-05-19T23:59:48Z Pharminent en 2026-05-19T23:59:38Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-19-2026/ 2026-05-19T23:45:57Z Pharminent en Oncology Intelligence Digest • May 19, 2026 2026-05-19T23:44:15Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-19-2026/ 2026-05-19T17:31:27Z Pharminent en Strategic News Watch • May 19, 2026 2026-05-19T17:31:16Z Blog https://pharminent.com/relay-doubles-the-bar-outpacing-novartis-with-a-60-response-in-rare-disease/ 2026-05-19T16:15:20Z Pharminent en Relay doubles the bar, outpacing Novartis with a 60% response in rare disease 2026-05-19T14:50:02Z Blog https://pharminent.com/biomarin-suffers-another-blow-to-rare-disease-portfolio-in-phase-3-flop/ 2026-05-19T16:15:39Z Pharminent en BioMarin suffers another blow to rare disease portfolio in Phase 3 flop 2026-05-19T11:48:58Z Blog https://pharminent.com/ucb-reports-positive-outcomes-for-bimekizumab-in-psoriatic-arthritis/ 2026-05-19T16:15:44Z Pharminent en UCB reports positive outcomes for bimekizumab in psoriatic arthritis 2026-05-19T11:48:33Z Blog https://pharminent.com/european-study-shows-inequality-in-access-to-new-medicines/ 2026-05-19T16:15:55Z Pharminent en European study shows inequality in access to new medicines 2026-05-19T11:27:19Z Blog https://pharminent.com/sanofi-says-drug-for-rare-disease-aatd-tops-standard-care/ 2026-05-19T16:16:00Z Pharminent en Sanofi says drug for rare disease AATD tops standard care 2026-05-19T10:13:40Z Blog https://pharminent.com/scotus-wont-hear-pharmas-ira-complaints/ 2026-05-19T16:16:06Z Pharminent en SCOTUS won't hear pharma's IRA complaints 2026-05-19T09:00:16Z Blog